Home/UbiVac/Dr. Bernard A. Fox
DB

Dr. Bernard A. Fox

Co-founder and CEO

UbiVac

Therapeutic Areas

UbiVac Pipeline

DrugIndicationPhase
DPV-001Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) and other solid tumorsPhase 2
Target Discovery PlatformNovel cancer antigen identification for multiple modalitiesDiscovery